Talawar
1 known investors
Talawar Therapeutics develops bispecific antibodies that combine two disease-driving pathways in a single therapy for greater and more durable treatment effect. Its lead program, TALA-125, is an anti-IL-13 x anti-IL-18 bispecific aimed at first-line patients and those who have failed prior therapies.
Biotech
Founders & leadership
SM
Steve MigauskyChief Legal and Administrative Officer
Investors · 1
Frequently asked questions
- What does Talawar do?
- Talawar Therapeutics develops bispecific antibodies that combine two disease-driving pathways in a single therapy for greater and more durable treatment effect. Its lead program, TALA-125, is an anti-IL-13 x anti-IL-18 bispecific aimed at first-line patients and those who have failed prior therapies.
- Who are Talawar's investors?
- Talawar's investors include Access Biotechnology.